Data shows that since the fourth quarter of 2024, the M&A activities of listed companies in the Traditional Chinese Medicine Sector of the A-share market have been intensive. In December alone, 12 companies released acquisition or merger announcements. A review of related announcements reveals that in recent M&A cases in the Traditional Chinese Medicine Industry, leading listed companies have been active; some choose to directly acquire new assets while others layout the Industry Chain through establishing Funds, joint ventures, and other methods. Meanwhile, many companies are also expanding into the fields of biochemical Innovative Drugs. Several analysts indicate that this round of M&A and restructuring among listed companies in the Traditional Chinese Medicine Sector is mainly due to recent policy support encouraging companies to enhance their development quality through mergers, as well as the active search for growth points by Traditional Chinese Medicine listed companies. (Securities Daily)